TNM-001 is under clinical development by Zhuhai Trinomab Pharmaceutical and currently in Phase I for Respiratory Syncytial Virus (RSV) Infections. According to GlobalData, Phase I drugs for Respiratory Syncytial Virus (RSV) Infections does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the TNM-001 LoA Report. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
TNM-001 overview
TNM-001 is under development for the treatment of respiratory syncytial virus (RSV) infections. The drug candidate acts by targeting respiratory syncytial virus fusion protein (RSV F Protein). The drug candidates are fourth generation human antibodies being developed based on natural whole human monoclonal antibody (HitMab) technology platform. It is administered through parenteral and intramuscular route.
Zhuhai Trinomab Pharmaceutical overview
Zhuhai Trinomab Pharmaceutical (Trinomab) is a biopharmaceutical company that develops natural human monoclonal antibodies and novel drugs to treat infectious diseases, autoimmune diseases, malignant tumors, and other diseases. It utilizes HitmAb, a monoclonal antibody research and development technology that has capabilities of integration to screen and discover human bodies with target pathogens. Trinomab’s product pipeline includes TNM001 to treat respiratory syncytial virus (RSV); TNM002 for tetanus prevention; and TNM005 for the treatment of varicella-zoster virus infection. The company is also developing various other drug programs to treat and prevent hCMV infection, bacterial septic shock, and rabies. It operates a production base in Zhuhai, China; and additional offices in Australia, China, and Switzerland. Trinomab is headquartered in Zhuhai, Guangdong, China.
For a complete picture of TNM-001’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
